Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
Tomokazu Tamura(Hokkaido University), Takasuke Fukuhara(Hokkaido University), Hayato Ito(Hokkaido University), Keita Matsuno(Sapporo International University), Rina Hashimoto(Kyoto University), Kei Sato(University of Tokyo Hospital), Jun Kanamune, Masumi Tsuda(Hokkaido University), Isao Yokota(Kyoto University), Mai Kishimoto(Tokyo University of Agriculture and Technology), Yoshitaka Oda(Hokkaido University), Hirofumi Sawa(Sapporo International University), Kazuo Takayama(Tokyo Medical University), Naganori Nao(Sapporo University), Yusuke Ohba(University of Tsukuba), Tetsuharu Nagamoto, Shinya Tanaka(Hokkaido University), Jumpei Ito(National Institute of Infectious Diseases), Yuki Yamamoto(National Center For Child Health and Development), Tomoko Kamasaki(Hokkaido University), Daichi Yamasoba(National Institute of Infectious Diseases), Rigel Suzuki(Hokkaido University), Lei Wang(Nanjing University of Science and Technology), Izumi Kimura(National Institute of Infectious Diseases), Kumiko Yoshimatsu(Hokkaido University), Yoichiro Fujioka(Hokkaido University of Science)
Cited by 7
Related Papers
Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
|Nature Immunology|2012|832
Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy
|New England Journal of Medicine|2018|551